These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 28462920)

  • 41. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.
    Cotte S; von Ahsen N; Kruse N; Huber B; Winkelmann A; Zettl UK; Starck M; König N; Tellez N; Dörr J; Paul F; Zipp F; Lühder F; Koepsell H; Pannek H; Montalban X; Gold R; Chan A
    Brain; 2009 Sep; 132(Pt 9):2517-30. PubMed ID: 19605531
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association and interaction between dietary patterns and gene polymorphisms in Liangshan residents with hyperuricemia.
    Li T; Li S; Tian T; Nie Z; Xu W; Liu L; Jia H
    Sci Rep; 2022 Jan; 12(1):1356. PubMed ID: 35079028
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Polymorphisms of
    Duong NT; Ngoc NT; Thang NTM; Phuong BTH; Nga NT; Tinh ND; Quynh DH; Ton ND; Hai NV
    Medicina (Kaunas); 2019 Jan; 55(1):. PubMed ID: 30621105
    [No Abstract]   [Full Text] [Related]  

  • 44. Brief Report: Selection of HIV-1 Variants With Higher Transmission Potential by 1% Tenofovir Gel Microbicide.
    Ngandu NK; Carlson JM; Chopera DR; Ndabambi N; Abdool Karim Q; Abdool Karim S; Williamson C
    J Acquir Immune Defic Syndr; 2017 Sep; 76(1):43-47. PubMed ID: 28797020
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Low raltegravir concentration in cerebrospinal fluid in patients with ABCG2 genetic variants.
    Tsuchiya K; Hayashida T; Hamada A; Kato S; Oka S; Gatanaga H
    J Acquir Immune Defic Syndr; 2014 Aug; 66(5):484-6. PubMed ID: 24872134
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Frequency and impact of DHODH, ABCG2 and CYP2C19 SNPs on the therapeutic efficacy, tolerability and toxicity of leflunomide.
    Makarem YS; Hareedy MS; Hassanien M; Ahmed EA; Hetta HF; Mohamed AA
    Pharmacogenomics; 2021 Dec; 22(18):1201-1209. PubMed ID: 34747629
    [No Abstract]   [Full Text] [Related]  

  • 47. Randomized trial of stopping or continuing ART among postpartum women with pre-ART CD4 ≥ 400 cells/mm3.
    Currier JS; Britto P; Hoffman RM; Brummel S; Masheto G; Joao E; Santos B; Aurpibul L; Losso M; Pierre MF; Weinberg A; Gnanashanmugam D; Chakhtoura N; Klingman K; Browning R; Coletti A; Mofenson L; Shapiro D; Pilotto J;
    PLoS One; 2017; 12(5):e0176009. PubMed ID: 28489856
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of Antiretroviral Therapy on Bone and Renal Health in Young Adults Infected With HIV in Early Life.
    Unsal AB; Mattingly AS; Jones SE; Purdy JB; Reynolds JC; Kopp JB; Hazra R; Hadigan CM
    J Clin Endocrinol Metab; 2017 Aug; 102(8):2896-2904. PubMed ID: 28531309
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Agreement between Estimated and Measured Renal Function in an Everyday Clinical Outpatient Setting of Human Immunodeficiency Virus-Infected Individuals.
    Ahlström MG; Kjær A; Gerstoft J; Obel N
    Nephron; 2017; 136(4):318-327. PubMed ID: 28472812
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of intensified antiretroviral therapy during early HIV infection on gut immunology and inflammatory blood biomarkers.
    Kim CJ; Rousseau R; Huibner S; Kovacs C; Benko E; Shahabi K; Kandel G; Ostrowski M; Kaul R
    AIDS; 2017 Jul; 31(11):1529-1534. PubMed ID: 28463882
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The ADVANCE study: a groundbreaking trial to evaluate a candidate universal antiretroviral regimen.
    Venter WDF; Clayden P; Serenata C;
    Curr Opin HIV AIDS; 2017 Jul; 12(4):351-354. PubMed ID: 28538284
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Osteoporosis and osteopenia are not associated with T-cell activation in older cART-treated HIV-infected patients.
    Krikke M; Klomberg RCW; van der Veer E; Tesselaar K; Verhaar HJJ; Hoepelman AIM; Arends JE
    Neth J Med; 2017 May; 75(4):138-144. PubMed ID: 28522769
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predictors of estimated glomerular filtration rate progression, stabilization or improvement after chronic renal impairment in HIV-positive individuals.
    Ryom L; Mocroft A; Kirk O; Reiss P; Ross M; Smith C; Moranne O; Morlat P; Fux CA; Sabin C; Phillips A; Law M; Lundgren JD;
    AIDS; 2017 Jun; 31(9):1261-1270. PubMed ID: 28492392
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Influence of Sex/Gender and Race on Responses to Raltegravir Combined With Tenofovir-Emtricitabine in Treatment-Naive Human Immunodeficiency Virus-1 Infected Patients: Pooled Analyses of the STARTMRK and QDMRK Studies.
    Squires K; Bekker LG; Katlama C; Yazdanpanah Y; Zhou Y; Rodgers AJ; DiNubile MJ; Sklar PA; Leavitt RY; Teppler H
    Open Forum Infect Dis; 2017; 4(1):ofw047. PubMed ID: 28480227
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Risk of Acute Liver Injury With Antiretroviral Therapy by Viral Hepatitis Status.
    Gowda C; Newcomb CW; Liu Q; Carbonari DM; Lewis JD; Forde KA; Goldberg DS; Reddy KR; Roy JA; Marks AR; Schneider JL; Kostman JR; Tate JP; Lim JK; Justice AC; Goetz MB; Corley DA; Lo Re V
    Open Forum Infect Dis; 2017; 4(2):ofx012. PubMed ID: 28470014
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Renal and bone effects of tenofovir-containing regimens compared in a large, real-world patient population.
    Tobin SC
    AIDS; 2017 Jul; 31(12):N17. PubMed ID: 28463886
    [No Abstract]   [Full Text] [Related]  

  • 57. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial.
    Markowitz M; Frank I; Grant RM; Mayer KH; Elion R; Goldstein D; Fisher C; Sobieszczyk ME; Gallant JE; Van Tieu H; Weinberg W; Margolis DA; Hudson KJ; Stancil BS; Ford SL; Patel P; Gould E; Rinehart AR; Smith KY; Spreen WR
    Lancet HIV; 2017 Aug; 4(8):e331-e340. PubMed ID: 28546090
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study.
    Cahn P; Rolón MJ; Figueroa MI; Gun A; Patterson P; Sued O
    J Int AIDS Soc; 2017 May; 20(1):21678. PubMed ID: 28537061
    [TBL] [Abstract][Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.